carmofur has been researched along with Carcinoma, Hepatocellular in 15 studies
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) was administered orally to 63 patients with hepatocellular carcinoma (HCC) at a daily dose of 200 to 600 mg." | 7.67 | [Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kubo, Y; Majima, Y; Ninomiya, F; Sakai, T; Sakemi, T; Sato, K; Shiraishi, K; Tanikawa, K, 1984) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) was orally administered at doses of 300-600 mg daily for 7-360 days to 27 inoperable cirrhotics with hepatocellular carcinoma." | 7.67 | [Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma]. ( Akiharu, W; Fujiwara, M; Higashi, T; Ito, T; Kobayashi, M; Nagashima, H; Nakatsukasa, H; Shiota, T; Yamamoto, H; Yamauchi, Y, 1984) |
| "The metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a drug prescribed for treating patients with hepatocellular carcinoma (HCC), was studied in relation to liver function, with the objective of clarifying the occurrence of any adverse side-effects on the central nervous system." | 7.67 | Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. ( Kanematsu, T; Shimada, M; Sugimachi, K; Takenaka, K, 1989) |
| "HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels." | 7.67 | [HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU]. ( Hamazaki, K; Mimura, H; Mori, M; Orita, K, 1989) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) was administered orally to 63 patients with hepatocellular carcinoma (HCC) at a daily dose of 200 to 600 mg." | 3.67 | [Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kubo, Y; Majima, Y; Ninomiya, F; Sakai, T; Sakemi, T; Sato, K; Shiraishi, K; Tanikawa, K, 1984) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) was orally administered at doses of 300-600 mg daily for 7-360 days to 27 inoperable cirrhotics with hepatocellular carcinoma." | 3.67 | [Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma]. ( Akiharu, W; Fujiwara, M; Higashi, T; Ito, T; Kobayashi, M; Nagashima, H; Nakatsukasa, H; Shiota, T; Yamamoto, H; Yamauchi, Y, 1984) |
| "The metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a drug prescribed for treating patients with hepatocellular carcinoma (HCC), was studied in relation to liver function, with the objective of clarifying the occurrence of any adverse side-effects on the central nervous system." | 3.67 | Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. ( Kanematsu, T; Shimada, M; Sugimachi, K; Takenaka, K, 1989) |
| "HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels." | 3.67 | [HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU]. ( Hamazaki, K; Mimura, H; Mori, M; Orita, K, 1989) |
| "Before proceeding with a resection of a hepatocellular carcinoma (HCC) in patients, the concentrations of 5-FU and 1-Hexylcarbamoyl-5-fluorouracil (HCFU) have been measured in the serum, the liver, and in the cancer tissue after an oral administration of HCFU (300 mg)." | 3.67 | [5-FU and HCFU concentrations in serum and tissues in hepatocellular carcinoma after HCFU oral administration]. ( Suenaga, M, 1988) |
| " After right lobectomy of the liver which contained the tumors of S6 2 cm and S8 3 cm in diameter 7 months before, the patient was treated with hepatic arterial embolization (TAE) combined with infusion of anti-cancer drug (ADM, CDDP) four times since June 1990." | 1.28 | [A case report of postoperative recurrent hepatocellular carcinoma effectively treated with HCFU administration combined with TAE]. ( Imai, Y; Ito, J; Kobayashi, K; Okamoto, M; Tagawa, K; Taniguchi, M; Tanzawa, Y; Toda, N; Unuma, T; Uta, Y, 1992) |
| "Six patients with hepatocellular carcinoma (HCC) and 9 patients with metastatic liver carcinoma (MLC) (4 with stomach cancer, 4 with pancreas cancer and 1 with colon cancer) were treated with rapid hepatic artery infusion of adriamycin." | 1.27 | [Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma]. ( Hino, I; Kimura, I; Kuroda, S; Numoto, A; Ohnoshi, T; Takahashi, M; Tsuji, M; Ueoka, H, 1984) |
| "407 cases of unresectable hepatocellular carcinoma (HCC) occurring from 1970 to March 1985, including 107 cases receiving conservative therapy, 176 cases receiving one-shot therapy and 124 cases receiving transcatheter arterial embolization (TAE) therapy, were studied and the efficacy of chemotherapy was compared with that of TAE therapy." | 1.27 | [One-shot therapy and transcatheter arterial embolization (TAE) therapy of unresectable hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kawazoe, Y; Kumagai, M; Tanikawa, K; Yamashita, K, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (66.67) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shiraishi, K | 1 |
| Kubo, Y | 1 |
| Majima, Y | 1 |
| Sato, K | 1 |
| Sakemi, T | 1 |
| Sakai, T | 1 |
| Hirai, K | 2 |
| Ninomiya, F | 1 |
| Abe, M | 2 |
| Tanikawa, K | 2 |
| Akiharu, W | 1 |
| Higashi, T | 1 |
| Kobayashi, M | 1 |
| Nakatsukasa, H | 1 |
| Fujiwara, M | 1 |
| Shiota, T | 1 |
| Yamauchi, Y | 1 |
| Ito, T | 1 |
| Yamamoto, H | 1 |
| Nagashima, H | 1 |
| Ueoka, H | 1 |
| Kuroda, S | 1 |
| Ohnoshi, T | 1 |
| Kimura, I | 1 |
| Numoto, A | 1 |
| Hino, I | 1 |
| Takahashi, M | 1 |
| Tsuji, M | 1 |
| Itsubo, M | 1 |
| Yamamoto, M | 1 |
| Arii, S | 1 |
| Sugahara, K | 1 |
| Tobe, T | 1 |
| Ono, T | 2 |
| Nagasue, N | 2 |
| Kohno, H | 2 |
| Hayashi, T | 1 |
| Uchida, M | 1 |
| Yukaya, H | 1 |
| Yamanoi, A | 2 |
| Nazmy El Assal, O | 1 |
| Imai, Y | 1 |
| Ito, J | 1 |
| Tanzawa, Y | 1 |
| Toda, N | 1 |
| Okamoto, M | 1 |
| Kobayashi, K | 1 |
| Taniguchi, M | 1 |
| Uta, Y | 1 |
| Tagawa, K | 1 |
| Unuma, T | 1 |
| Kanda, Y | 1 |
| Akazawa, S | 1 |
| Futatsugi, K | 1 |
| Fujiki, T | 1 |
| Saifuku, K | 1 |
| Yamamoto, K | 1 |
| Suzuki, F | 1 |
| Nakajima, T | 1 |
| Naoi, Y | 1 |
| Muraoka, M | 1 |
| Takenaka, K | 2 |
| Kanematsu, T | 2 |
| Shimada, M | 1 |
| Sugimachi, K | 2 |
| Mori, M | 1 |
| Hamazaki, K | 1 |
| Mimura, H | 1 |
| Orita, K | 1 |
| Higashi, H | 1 |
| Matsumata, T | 1 |
| Yoshida, Y | 1 |
| Suenaga, M | 1 |
| Kawazoe, Y | 1 |
| Yamashita, K | 1 |
| Kumagai, M | 1 |
| Onji, M | 1 |
| Kondo, H | 1 |
| Yamashita, Y | 1 |
| Ohta, Y | 1 |
| Mori, K | 1 |
| Fuse, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection[NCT05161143] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for carmofur and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepa | 2001 |
2 trials available for carmofur and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Flu | 1996 |
Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1997 |
12 other studies available for carmofur and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
[Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorou | 1984 |
[Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C | 1984 |
[Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma].
Topics: Adult; Aged; Alkaline Phosphatase; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Sched | 1984 |
[The present status of chemotherapy for hepatocellular carcinoma].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1993 |
[A case report of postoperative recurrent hepatocellular carcinoma effectively treated with HCFU administration combined with TAE].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeut | 1992 |
[A case of hepatocellular carcinoma (HCC) with lung metastasis which responded to chemotherapy with a single use of 1-hexylcarbamoyl-5-fluorouracil (HCFU)].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Lung Neopla | 1989 |
Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans; Liver Cirrhosis; Liv | 1989 |
[HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans | 1989 |
[1-Hexylcarbamoyl-5-fluorouracil (HCFU) effective in hepatocellular carcinoma metastatic to the lungs--a case report].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; | 1987 |
[5-FU and HCFU concentrations in serum and tissues in hepatocellular carcinoma after HCFU oral administration].
Topics: Administration, Oral; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver; Liver Neoplasms | 1988 |
[One-shot therapy and transcatheter arterial embolization (TAE) therapy of unresectable hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Embolization | 1985 |
[Blood level of 5-fluorouracil (5-FU) by oral administration of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and tegafur in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; | 1985 |